Company intelligence / Profile preview

Targeted Therapy Technologies

Irvine, California, United States3tophthalmics.com ↗

Ownership: Private
Development stage: Other

Overview

The company’s lead program is episcleral topotecan for pediatric intraocular retinoblastoma. It has received FDA Breakthrough Therapy Designation and is in Phase 2 clinical trials. The technology enables local, non-invasive delivery of small molecules to the eye without penetrating the globe, aiming to improve efficacy and safety over existing treatments

Therapeutic areas: OphthalmologyOncology
Modalities: Small moleculeDrug delivery device (episcleral drug delivery system)
Industry: Biotech

Drug pipeline

1 asset

Episcleral Topotecan

Phase 1

Indications: Retinoblastoma

Partnerships

U.S. Food and Drug Administration / HHS grant support for clinical trial funding

Beyond the preview

Go deeper on Targeted Therapy Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Targeted Therapy Technologies.

Explore the full profile